It’s being called an amazing new drug that could have big implications for patients at risk of heart attack or stroke.

The drug is called Jardiance, and a recent study found that clinical trial subjects who took it were 38 percent less likely to die form a heart attack, a stroke, or another cardiovascular issues compared to those who took a placebo, according to a Los Angeles Times report.

Also, those who took Jardiance were 35 percent less likely to get hospitalized for heart failure and 32 percent less likely to die of anything, not just heart disease.

The findings, published in the New England Journal of Medicine, was a rare bit of good news in the world of diabetes treatments, and an impressive success story that could have massive implications for how these conditions are treated.

Other drugs that have been tested haven’t shown that they reduce the number of heart attacks or other cardiovascular deaths, and sometimes they even were associated with a high risk of it. But Jardiance was the first diabetes drug that showed evidence of a cardiovascular benefit.

The generic version of Jardiance is empagliflozin. It is part of a new class of drugs that is meant to reduce the blood sugar in diabetes patients, and it was cleared by the U.S. Food and Drug Administration last year for marketing in the United States. It costs about $350 per month, a price tag that has caused Britain’s National Health Service to balk, saying it’s not cost-effective.

The makers of Jardiance conducted a new clinical trial at the behest of the FDA.

Those involved in the study were at a particularly high risk of an early cardiovascular death.